Helén Tuvesson

Ac­tive Biotech is back, with one last bid for the failed MS drug Te­va dis­card­ed

Laquin­i­mod was the drug that was go­ing to save Te­va.

Over 14 years, the Is­raeli phar­ma start­ed the com­pound on at least 15 clin­i­cal tri­als, 6 of them Phase III. They want­ed it to re­place the block­buster mul­ti­ple scle­ro­sis drug Co­pax­one. But it failed late-stage study af­ter late-stage study, not on­ly in MS but al­so Hunt­ing­ton’s. And in 2018, af­ter the fourth ma­jor whiff in 18 months, Te­va re­turned the drug and all its rights back to sender: Swe­den’s Ac­tive Bio.

Now, Ac­tive says they’re try­ing again: in Crohn’s dis­ease and eye dis­or­ders.

Af­ter van­ish­ing from head­lines for a year and a half fol­low­ing Te­va’s with­draw­al, Ac­tive an­nounced it has been con­duct­ing a 6-month long re­view and is now an­nounc­ing “a new di­rec­tion for the com­pa­ny.” The re­ori­en­ta­tion is an all-but emer­gency mea­sure to sal­vage a biotech whose fu­ture has been in jeop­ardy since even be­fore their ma­jor part­ner de­part­ed.

It will in­volve halt­ing two ear­ly-stage projects, and an­oth­er bid to keep laquin­i­mod alive. The com­pa­ny has long shown far greater faith in the as­set than out­side ob­servers, spot­light­ing the clin­i­cal ac­tiv­i­ty even in tri­als where the pri­ma­ry and sec­ondary end­point failed.

When Te­va walked away, Ac­tive said it would con­tin­ue ex­plor­ing the drug as a treat­ment for neu­rode­gen­er­a­tion, but now, based in part on a Phase IIa study pub­lished in 2014, they say the clear­est prospect is Crohn’s dis­ease. They’ll al­so spend the next 12 months study­ing re­sults in wet AMD and uveitis pre­clin­i­cal­ly. Any Hunt­ing­ton’s and MS ef­forts are over, they said.

Two oth­er drugs are in play. Tasquin­i­mod, an im­munomod­u­la­tor, will en­ter a Phase Ib/IIa tri­al on mul­ti­ple myelo­ma in part­ner­ship with the Uni­ver­si­ty of Penn­syl­va­nia Med­ical School. Nap­tu­momab, part­nered with NeoTX, is in Phase Ia/IIb for sol­id tu­mors. Pro­jects for im­mune-mod­u­lat­ing com­pounds paquin­i­mod and SILC have been aban­doned.

Ac­tive Biotech first no­ti­fied the pub­lic of its pre­car­i­ous sit­u­a­tion in De­cem­ber 2017, af­ter the sec­ond ma­jor laquin­i­mod MS fail­ure, telling share­hold­ers it “lacks fund­ing to en­sure its op­er­a­tions for the com­ing twelve-month pe­ri­od.” CEO Helén Tu­ves­son, ap­point­ed in mid-2017, moved swift­ly af­ter Te­va’s de­par­ture, most no­tably sell­ing their prop­er­ty in Lund for 275 mil­lion SEK  (~$29 mil­lion).

Te­va, mean­while, has watched the Co­pax­one com­pe­ti­tion they hoped to head off come in full force. No­var­tis and My­lan each now have copy­cats on the mar­ket. And rev­enues from the drug have fall­en pre­cip­i­tous­ly in the last 2.5 years, from a peak of $842 mil­lion in the sec­ond quar­ter of 2017, to $271 mil­lion as of Q3 2019. Still, that’s less of a drop-off than some an­a­lysts ex­pect­ed and have helped keep the com­pa­ny afloat amid oth­er prob­lems across their busi­ness, in­clud­ing a fal­ter­ing gener­ics busi­ness and the law­suits they face for their role in the opi­oid abuse epi­dem­ic.

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Sanofi is officially giving up on its oral SERD.

The French drugmaker put out word Wednesday morning that it will discontinue the global development program of amcenestrant, the selective estrogen receptor degrader once billed as a top late-stage prospect. Having already failed a Phase II monotherapy test earlier this year, a combo with the drug also missed the bar in a second trial for breast cancer, triggering the decision to drop the whole program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Tom Barnes, Orna Therapeutics CEO

UP­DAT­ED: 'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

Merck went in deep on its collaboration with Moderna on new mRNA programs, and dropped them all over time, including their RSV partnership. But after writing off what turned out as one of the most successful infectious disease players in the business, Merck is coming in this morning with a new preclinical alliance — this time embracing a biotech that hopes to eventually outdo the famously successful mRNA in a new run at vaccines and therapeutics.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Kate Haviland, Blueprint Medicines CEO

Blue­print met all its end­points in bid for ex­pand­ed Ay­vak­it la­bel — but stock trends low­er any­way

Blueprint Medicines announced this morning that the second part of its study on Ayvakit in non-advanced systemic mastocytosis (SM) — a rare disease in which a type of white blood cells known as mast cells builds up — met all endpoints, but the biopharma left key questions unanswered.

In 212 patients, with 141 in the treatment arm and 71 in the control arm, patients who got Ayvakit saw an average 15.6-point decrease in their symptom scores compared to a 9.2-point decrease in the placebo arm at 24 weeks. In an extension study, those on Ayvakit saw their symptom scores drop by 20.2 points by week 48.

Bayer's first DTC ad campaign for chronic kidney disease drug Kerendia spells out its benefits

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

Do you know the ABCs of CKD in T2D? Bayer’s first ad campaign for Kerendia tackles the complexity of chronic kidney disease with a play on the acronym (CKD) and its connection to type 2 diabetes (T2D).

Kerendia was approved last year as the first and only non-steroidal mineralocorticoid receptor antagonist to treat CKD in people with type 2 diabetes.

In the TV commercial launched this week, A is for awareness, B is for belief and C is for cardiovascular, explained in the ad as awareness of the connection between type 2 and kidney disease, belief that something can be done about it, and cardiovascular events that may be reduced with treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

James Mock, incoming CFO at Moderna

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

When Moderna hired a new CFO last year,  it didn’t expect to see him gone after only one day. Today the biotech named his — likely much more vetted — replacement.

The mRNA company put out word early Wednesday that after the untimely departure of then brand-new CFO Jorge Gomez, it has now found a replacement in James Mock, the soon-to-be former CFO at diagnostics and analytics company PerkinElmer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has landed a new first from UNICEF the first-ever contract for malaria vaccines, worth up to $170 million for 18 million vaccine doses distributed over the next three years.

The vaccine, known as Mosquirix or RTS,S, won WHO’s backing last October after a controversial start, but UNICEF said these doses will potentially save thousands of lives every year.

“We hope this is just the beginning,” Etleva Kadilli, director of UNICEF’s supply division, said. “Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market. This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.”

Joe Jonas (Photo by Anthony Behar/Sipa USA)(Sipa via AP Images)

So­lo Jonas broth­er car­ries Merz's new tune in Botox ri­val cam­paign

As the lyrics of his band’s 2019 pop-rock single suggest, Joe Jonas is only human — and that means even he gets frown lines. The 33-year-old singer-songwriter is Merz’s newest celebrity brand partner for its Botox rival Xeomin, as medical aesthetics brands target a younger audience.

Merz kicked off its “Beauty on Your Terms” campaign on Tuesday, featuring the Jonas brother in a video ad for its double-filtered anti-wrinkle injection Xeomin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Marisol Peron, Genmab SVP of communications and corporate affairs

Gen­mab launch­es cor­po­rate cam­paign am­pli­fy­ing its ‘knock your socks off’ an­ti­bod­ies

Genmab often talks about its “knock-your-socks-off” antibodies — and now the term is getting its own logo and corporate campaign.

The teal and purple logo for the acronym KYSO — Genmab pronounces it “ky-so” — debuts on Wednesday and comes on the heels of Genmab’s newly announced 2030 vision. That aspiration aims to expand Genmab’s drug development beyond oncology to include other serious diseases, while also doubling down on its own drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.